# XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

> **NCT04674137** · PHASE2 · COMPLETED · sponsor: **Chemlmmune Therapeutics LLC** · enrollment: 70 (actual)

## Conditions studied

- Bronchial Asthma
- Eosinophilic Asthma

## Interventions

- **DRUG:** XC8 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04674137
- **Lead sponsor:** Chemlmmune Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2021-08-27
- **Final completion:** 2021-08-27
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04674137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04674137, "XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04674137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*